Literature DB >> 30946993

Mitochondrial metabolic stroke: Phenotype and genetics of stroke-like episodes.

Josef Finsterer1.   

Abstract

Stroke-like episodes (SLEs) are the hallmark of mitochondrial encephalopathy with lactic acidosis and stroke-like episode (MELAS) syndrome but rarely occur also in other specific or nonspecific mitochondrial disorders. Pathophysiologically, SLLs are most likely due to a regional disruption of the blood-brain barrier triggered by the underlying metabolic defect, epileptic activity, drugs, or other factors. SLEs manifest clinically with a plethora of cerebral manifestations, which not only include features typically seen in ischemic stroke, but also headache, epilepsy, ataxia, visual impairment, vomiting, and psychiatric abnormalities. The morphological correlate of a SLE is the stroke-like lesion (SLL), best visualised on multimodal MRI. In the acute stages, a SLL presents as vasogenic edema but may be mixed up with cytotoxic components. Additionally, SLLs are characterized by hyperperfusion on perfusion studies. In the chronic stage, SLLs present with a colorful picture before they completely disappear, or end up as white matter lesion, cyst, laminar cortical necrosis, focal atrophy, or as toenail sign. Treatment of SLLs is symptomatic and relies on recommendations by experts. Beneficial effects have been reported with nitric-oxide precursors, antiepileptic drugs, antioxidants, the ketogenic diet, and steroids. Lot of research is still needed to uncover the enigma SLE/SLL.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antioxidants; Genetics; L-arginine; Mitochondrial; Oxidative metabolism; Steroids; Stroke; Stroke mimic; Treatment

Mesh:

Substances:

Year:  2019        PMID: 30946993     DOI: 10.1016/j.jns.2019.03.021

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  15 in total

1.  Stroke-like Episodes in m.3243A≥G Carriers Need to Be Monitored by MRI Starting with the Onset of Clinical Manifestations.

Authors:  J Finsterer
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-06       Impact factor: 3.825

2.  Disseminated stroke-like episodes lesions in MELAS are partially reversible with lactate disappearance.

Authors:  Yuya Kobayashi; Seishu Karasawa; Nobuhiko Ohashi; Kanji Yamamoto
Journal:  Acta Neurol Belg       Date:  2022-06-08       Impact factor: 2.396

3.  A Boy with Spells of Unusual Movements After Failure in Exam.

Authors:  Devangi Desai; Soaham Desai
Journal:  Mov Disord Clin Pract       Date:  2021-09-03

4.  Ischemic and Metabolic Stroke Can Co-occur in m.3243A>G Carriers: A Case Report.

Authors:  Josef Finsterer; Sinda Zarrouk
Journal:  Cureus       Date:  2022-06-07

5.  Cluster headache as a manifestation of a stroke-like episode in a carrier of the MT-ND3 variant m.10158T>C.

Authors:  Josef Finsterer
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

6.  The metabolic hypothesis is more likely than the epileptogenic hypothesis to explain stroke-like lesions.

Authors:  Josef Finsterer
Journal:  Wellcome Open Res       Date:  2020-06-24

7.  Commentary: New Variant of MELAS Syndrome With Executive Dysfunction, Heteroplasmic Point Mutation in the MT-ND4 Gene (m.12015T>C; p.Leu419Pro) and Comorbid Polyglandular Autoimmune Syndrome Type 2.

Authors:  Josef Finsterer
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

8.  Reply to: 'Advances in imaging of brain abnormalities in neuromuscular disease'.

Authors:  Josef Finsterer
Journal:  Ther Adv Neurol Disord       Date:  2019-09-27       Impact factor: 6.570

9.  Commentary: Epilepsy in Leigh Syndrome With Mitochondrial DNA Mutations.

Authors:  Josef Finsterer
Journal:  Front Neurol       Date:  2019-10-21       Impact factor: 4.003

10.  Metabolic or Ischemic Stroke in Succinic Semi-aldehyde Dehydrogenase Deficiency Due to the Homozygous Variant c. 1343 + 1_1343 + 3delGTAinsTT in ALDH5A1.

Authors:  Josef Finsterer; Carla A Scorza; Fulvio A Scorza; Ritwik Ghosh
Journal:  Ann Indian Acad Neurol       Date:  2020-06-05       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.